AssetMark Inc
JBIO icon

AssetMark Inc’s Jade Biosciences JBIO Stock Holding History

AssetMark Inc’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14 Hold
1
– – ﹤0.01% 3754
2026
Q2 		$22 Hold
1
– – ﹤0.01% 3532
2026
Q1 		$14 Hold
1
– – ﹤0.01% 3425
2025
Q4 		$15 Hold
1
– – ﹤0.01% 3359
2025
Q3 		$9 Hold
1
– – ﹤0.01% 3174
2025
Q2 		$10 Buy
+1
New +$34 ﹤0.01% 2993

Other funds holding JBIO

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Arizona State Retirement System
Arizona State Retirement System Phoenix, Arizona $20.3B AUM 36.55% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

AssetMark Inc's JBIO Position: Q3 2026 in Review

AssetMark Inc held its Jade Biosciences (JBIO) position steady in Q3 2026 at 1 share worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #3754.

AssetMark Inc first reported a position in JBIO in Q2 2025 and has held it in 6 quarters since. The position peaked at $22 in Q2 2026. 28 funds tracked by Wall St. Rank hold JBIO as of Q3 2026.

  • AssetMark Inc held 1 share of Jade Biosciences worth $14 as of Q3 2026.
  • AssetMark Inc left its Jade Biosciences share count unchanged in Q3 2026.
  • Jade Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3754 holding.
  • AssetMark Inc first reported a position in Jade Biosciences in Q2 2025 and has held it in 6 quarters since.
  • AssetMark Inc's Jade Biosciences position peaked at $22 in Q2 2026.
  • 28 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.